Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana

Medical Mycology

Volumn 47, Issue 1, 2009, Pages 45-49

  Marine, Marçal ^a   Pastor, F Javier ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Animal models; Flucytosine; Micafungin; Phaeohyphomycosis; Posaconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; FLUCYTOSINE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ABSCESS; CLADOPHIALOPHORA BANTIANA; CLADOSPORIUM; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; FUNGUS ISOLATION; MALE; MONITORING; MONOTHERAPY; MOUSE; MYCOSIS; NONHUMAN; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASCOMYCOTA; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FLUCYTOSINE; HUMANS; LIPOPEPTIDES; MALE; MICE; MYCOSES; TREATMENT OUTCOME; TRIAZOLES;

ANIMALIA; CLADOPHIALOPHORA BANTIANA; MURINAE;

EID: 58149199645     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780802526840     Document Type: Article

References (21)

1. Dixon, DM, Walsh, TJ Merz, WG et al. (1989) Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis, 11, pp. 515-525.
2. Kantarcioglu, AS and de Hoog, GS. (2004) Infections of the central nervous system by melanized fungi: A review of cases presented between 1999 and 2004. Mycoses, 47, pp. 4-13.
3. Chakrabarti, A. (2007) Epidemiology of central nervous system mycoses. Neurol India, 55, pp. 191-197.
4. Revankar, SG, Sutton, DA and Rinaldi, MG. (2004) Primary central nervous system phaeohyphomycosis: A review of 101 cases. Clin Infect Dis, 38, pp. 206-216.
5. Dixon, DM and Polak, A. (1987) In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy, 33, pp. 129-140.
6. Block, ER, Jennings, AE and Bennett, JE. (1973) Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine. Antimicrob Agents Chemother, 3, pp. 95-98.
7. Al-Abdely, HM, Najvar, LK Bocanegra, R. et al. (2005) Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother, 49, pp. 1701-1707.
8. Espinel-Ingroff, A. (2003) In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: Review of the literature. Rev Iberoam Micol, 20, pp. 121-136.
9. Sugar, AM and Liu, XP. (2001) Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother, 45, pp. 601-604.
10. Ortoneda, M., Capilla, J. Pujol, I. et al. (2002) Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. J Antimicrob Chemother, 49, pp. 525-529.
11. Luque, JC, Clemons, KV and Stevens, DA. (2003) Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother, 47, pp. 1452-1455.
12. Graybill, JR. (2000) The role of murine models in the development of antifungal therapy for systemic mycoses. Drug Resist Update, 3, pp. 364-383.
13. Serena, C., Pastor, FJ Marine, M. et al. (2007) Efficacy of voriconazole in a murine model of cryptococcal central nervous system infection. J Antimicrob Chemother, 60, pp. 162-165.
14. Dannaoui, E., Meis, JF, Loebenberg, D. and Verweij, PE. (2003) Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother, 47, pp. 3647-3650.
15. Clemons, KV and Stevens, DA. (2006) Animal models testing monotherapy versus combination antifungal therapy: Lessons learned and future directions. Curr Opin Infect Dis, 19, pp. 360-364.
16. Imai, JK, Singh, G. Clemons, KV et al. (2004) Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother, 48, pp. 4063-4066.
17. Pitisuttithum, P., Negroni, R. Graybill, JR et al. (2005) Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother, 56, pp. 745-755.
18. Joseph, JM, Jain, R. and Danziger, LH. (2007) Micafungin: A new echinocandin antifungal. Pharmacotherapy, 27, pp. 53-67.
19. Petraitis, V., Petraitiene, R. Groll, AH et al. (2002) Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother, 46, pp. 1857-1869.
20. Guembe, M., Guinea, J. Pelaez, T. et al. (2007) Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob Agents Chemother, 51, pp. 3457-3458.
21. Catalan, M. and Montejo, JC. (2006) Systemic antifungals. Pharmacodynamics and pharmacokinetics. Rev Iberoam Micol, 23, pp. 39-49.